Liver Cirrhosis Market to Witness Steady CAGR by 2036 Across the 7MM | DelveInsight

DelveInsight's "Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Liver Cirrhosis, historical and forecasted epidemiology and the Liver Cirrhosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Liver Cirrhosis Market Report @ https://www.delveinsight.com/report-store/liver-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Liver Cirrhosis Market Report
• In September 2026, AstraZeneca announced result of A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO).
• In August 2026, Kiminori Kimura, MD announced result of A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia.
• In August 2026, Can-Fite BioPharma continued the Phase III development of namodenoson for advanced hepatocellular carcinoma in patients with underlying Child-Pugh B7 liver cirrhosis, supporting its potential role in the treatment of liver disease-associated cancer.
• Within the 7MM, there are more than 3 million diagnosed prevalent cases of Liver Cirrhosis in 2025.
• The US showed the highest diagnosed prevalent population of Liver Cirrhosis compared to the other 7MM countries, with more than 2 million cases in 2025, accounting for nearly 61% of total diagnosed prevalent cases in the 7MM, followed by Japan, contributing 15% of all Liver Cirrhosis cases.
• The etiology-specific distribution of diagnosed prevalent cases of Liver Cirrhosis showed NASH, HCV, HVB, ALD, and PBC comprised 28%, 27%, 11%, 33%, and 2% cases, respectively, in the 7MM in 2025.
• EU4 and the UK accounted for approximately 1 million diagnosed prevalent cases of Liver Cirrhosis in 2025, with Germany accounting for the highest number of diagnosed prevalent cases between EU4 and the UK.
• Japan accounted for more than 500,000 cases of the total diagnosed prevalent cases of Liver Cirrhosis in the 7MM in 2025.
• The Liver Cirrhosis Companies include Akero Therapeutics and Galectin Therapeutics, among others.
• Promising Liver Cirrhosis Therapies include Efruxifermin and Belapectin, among others.

Get a Free sample for the Liver Cirrhosis Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/liver-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Liver Cirrhosis?
Cirrhosis is an advanced liver condition in which chronic injury causes healthy liver tissue to be replaced by scar tissue and regenerative nodules, impairing normal liver function and potentially causing portal hypertension and end-stage liver disease. Common causes include alcoholic liver disease, nonalcoholic fatty liver disease, and chronic hepatitis B or C. Early-stage cirrhosis is often asymptomatic and may be discovered incidentally through blood tests or imaging. Although liver biopsy remains the diagnostic gold standard, its invasive nature limits its use. Existing imaging and liver function tests may have limited sensitivity for early disease, emphasizing the need for reliable, non-invasive biomarkers for early detection and monitoring.

Liver Cirrhosis Epidemiology Segmentation in the 7MM
• Total Liver Cirrhosis Prevalent Cases
• Total Liver Cirrhosis Diagnosed Prevalent Cases
• Liver Cirrhosis Gender-specific Diagnosed Prevalent Cases
• Liver Cirrhosis Age-specific Diagnosed Prevalent Cases
• Etiology-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Liver Cirrhosis epidemiology trends @ https://www.delveinsight.com/report-store/liver-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Liver Cirrhosis Treatment Landscape
Liver cirrhosis treatment varies according to its underlying cause and disease severity. While cirrhosis is usually irreversible, early treatment of conditions such as viral hepatitis or hemochromatosis can slow progression, reduce complications, and potentially improve liver damage. Supportive care, including a balanced high-protein diet, regular physical activity, and correction of nutritional deficiencies, can further support overall health. Decompensated cirrhosis may cause ascites, hepatic encephalopathy, and variceal bleeding, requiring intensive management. Available treatments include medications, antibiotics, endoscopic interventions, and hemodialysis, although these may involve substantial costs and side effects. Liver transplantation remains the definitive option for end-stage disease, but limited donor availability remains a challenge.

Liver Cirrhosis Pipeline Analysis
• Efruxifermin: Akero Therapeutics
Efruxifermin (EFX), formerly AKR-001, is Akero's lead product candidate for MASH cirrhosis. EFX is designed to offer convenient once-weekly SC dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine if approved. EFX is currently being evaluated in Phase IIb clinical trials in patients with biopsy-confirmed NASH: the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Currently, the drug is in Phase II of clinical development for the treatment of MASH cirrhosis.

• Belapectin: Galectin Therapeutics
Belapectin, a Galectin 3 inhibitor administered via the IV route, is in Phase III development for the treatment of MASH cirrhosis.

Discover more about therapies set to grab major Liver Cirrhosis market share @ https://www.delveinsight.com/sample-request/liver-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Liver Cirrhosis Market Outlook
The Liver Cirrhosis Therapeutics Market is expected to increase, driven by the rising Liver Cirrhosis prevalence population, technological advancements, and upcoming therapies in the forecast period (2026-2036). The market is further expected to become increasingly competitive as multiple novel therapies targeting fibrosis, inflammation, metabolic dysfunction, and liver regeneration advance through clinical development. The potential introduction of effective disease-modifying treatments could significantly transform the Liver Cirrhosis Treatment landscape, improve patient outcomes, and accelerate overall market growth at a notable CAGR during the forecast period.

Scope of the Liver Cirrhosis Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025
• Forecast Period: 2026-2036
• Base Year: 2025
• Coverage: 7MM (US, EU4 [Germany, France, Italy, Spain], UK, Japan)
• Liver Cirrhosis Companies: Akero Therapeutics, Galectin Therapeutics, and others
• Liver Cirrhosis Therapies: Efruxifermin, Belapectin, and others
• Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and emerging therapies
• Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Attribute Analysis
• Liver Cirrhosis Unmet Needs, KOL's views, Market Segmented by Total Market Size, Market Size by Therapies, and Class of Therapies

To know more about Liver Cirrhosis companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/liver-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Liver Cirrhosis Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview: Liver Cirrhosis
8. Epidemiology and Patient Population
9. Patient Journey: Liver Cirrhosis
10. Emerging Therapies
11. Liver Cirrhosis: Seven Major Market Analysis
12. Key Opinion Leaders' Views
13. Unmet Needs
14. SWOT Analysis
15. Liver Cirrhosis Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.